Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Raloxifene · Evista, LY-139481

Small molecule · Modulator of Estrogen receptor alpha (ESR1) and Estrogen receptor beta (ESR2) · developed by Lilly

Approved FDA, Dec 1997
1 Registered trials

What is Raloxifene?

Raloxifene is a selective estrogen receptor modulator (SERM) that binds estrogen receptors and acts as an estrogen agonist in some tissues, such as bone, and as an antagonist in others, such as breast and uterine tissue. It is studied in osteoporosis and in reducing the risk of invasive breast cancer in postmenopausal women.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Evista, LY-139481, NSC-747974
Drug type
Small molecule
Targets
Estrogen receptor alpha (ESR1), Estrogen receptor beta (ESR2)
Mechanism
Modulator of Estrogen receptor alpha (ESR1) and Estrogen receptor beta (ESR2)
Pathways
estrogen receptor signaling, bone resorption and turnover, coactivator and corepressor recruitment at ER target gene promoters
Therapy area
Musculoskeletal
Developer
Lilly
In trials of
LGND
FDA status
Approved as Evista (December 9, 1997), NDA020815 · FDA label
UNII
YX9162EO3I

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 11, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00163137 Phase 3 Osteoporosis Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoporosis

Other drugs acting on ESR1 / ESR2

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.